Instantaneous Bethe-Salpeter Equation and Its Exact Solution

We present an approach to solve a Bethe-Salpeter (BS) equation exactly without any approximation if the kernel of the BS equation exactly is instantaneous, and take positronium as an example to illustrate the general features of the solutions. As a middle stage, a set of coupled and self-consistent integration equations for a few scalar functions can be equivalently derived from the BS equation always, which are solvable accurately. For positronium, precise corrections to those of the Schr\"odinger equation in order $v$ (relative velocity) in eigenfunctions, in order $v^2$ in eigenvalues, and the possible mixing, such as that between $S$ ($P$) and $D$ ($F$) components in $J^{PC}=1^{--}$ ($J^{PC}=2^{++}$) states as well, are determined quantitatively. Moreover, we also point out that there is a problematic step in the classical derivation which was proposed first by E.E. Salpeter. Finally, we emphasize that for the effective theories (such as NRQED and NRQCD etc) we should pay great attention on the corrections indicated by the exact solutions.Comment: 4 pages, replace for shortening the manuscrip

Quark-gluon plasma phenomenology from the lattice

The FASTSUM Collaboration has calculated several quantities relevant for QCD studies at non-zero temperature using the lattice technique. We report here our results for the (i) interquark potential in charmonium; (ii) bottomonium spectral functions; and (iii) electrical conductivity. All results were obtained with 2+1 flavours of dynamical fermions on an anisotropic lattice which allows greater resolution in the temporal direction.Comment: Plenary talk presented at the Strangeness in Quark Matter SQM 2013, Birmingham UK, 21-27 July 201

Factor 11 single-nucleotide variants in women with heavy menstrual bleeding

In a previous study it was shown that lower factor XI (FXI) levels in women with heavy menstrual bleeding (HMB). Our aim was to determine the single-nucleotide variants (SNVs) in the F11 gene in women with HMB. In addition, an extensive literature search was performed to determine the clinical significance of each SNV. Patients referred for HMB (PBAC-score >100) were included. With direct sequencing analysis of all 15 exons and flanking introns of the F11 gene, 29 different non-structural SNVs were detected in 49 patients with HMB. Interestingly, most of these SNVs have previously been associated with venous thrombosis instead of bleeding. These findings have not helped to elucidate the molecular basis of HMB. They also question the specificity of previously reported F11 variations in patients with thrombosis. More studies are needed to explain the lower FXI levels seen in patients with HMB

NEMO oligomerization and its ubiquitin-binding properties

The IKK [IκB (inhibitory κB) kinase] complex is a key regulatory component of NF-κB (nuclear factor κB) activation and is responsible for mediating the degradation of IκB, thereby allowing nuclear translocation of NF-κB and transcription of target genes. NEMO (NF-κB essential modulator), the regulatory subunit of the IKK complex, plays a pivotal role in this process by integrating upstream signals, in particular the recognition of polyubiquitin chains, and relaying these to the activation of IKKα and IKKβ, the catalytic subunits of the IKK complex. The oligomeric state of NEMO is controversial and the mechanism by which it regulates activation of the IKK complex is poorly understood. Using a combination of hydrodynamic techniques we now show that apo-NEMO is a highly elongated, dimeric protein that is in weak equilibrium with a tetrameric assembly. Interaction with peptides derived from IKKβ disrupts formation of the tetrameric NEMO complex, indicating that interaction with IKKα and IKKβ and tetramerization are mutually exclusive. Furthermore, we show that NEMO binds to linear di-ubiquitin with a stoichiometry of one molecule of di-ubiquitin per NEMO dimer. This stoichiometry is preserved in a construct comprising the second coiled-coil region and the leucine zipper and in one that essentially spans the full-length protein. However, our data show that at high di-ubiquitin concentrations a second weaker binding site becomes apparent, implying that two different NEMO–di-ubiquitin complexes are formed during the IKK activation process. We propose that the role of these two complexes is to provide a threshold for activation, thereby ensuring sufficient specificity during NF-κB signalling

Black holes and the quark-gluon plasma

I discuss the possibility that the quark-gluon plasma at strong coupling admits a description in terms of a black hole in asymptotically anti-de Sitter space.Comment: 19 pages, prepared for the Proceedings of Recent Developments in Gravity - NEB XIII, Thessaloniki, Greece, June 200

The local structure of molecular reaction intermediates at surfaces

A critical review is presented of the results of (experimental) quantitative structural studies of molecular reaction intermediates at surfaces; i.e. molecular species that do not exist naturally in the gas phase and, in most cases, are implicated in surface catalytic processes. A brief review of the main experimental methods that have contributed to this area is followed by a summary of the main results. Investigated species include: carboxylates, RCOO– (particularly formate, but also deprotonated amino acids); methoxy, CH3O–; carbonate, CO3; ethylidyne, CH3C–; NHx and SOx species; cyanide, CN. As far as possible in the limited range of systems studied, a few general trends are identified

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

mTOR (mammalian target of rapamycin) stimulates cell growth by phosphorylating and promoting activation of AGC (protein kinase A/protein kinase G/protein kinase C) family kinases such as Akt (protein kinase B), S6K (p70 ribosomal S6 kinase) and SGK (serum and glucocorticoid protein kinase). mTORC1 (mTOR complex-1) phosphorylates the hydrophobic motif of S6K, whereas mTORC2 phosphorylates the hydrophobic motif of Akt and SGK. In the present paper we describe the small molecule Ku-0063794, which inhibits both mTORC1 and mTORC2 with an IC50 of ∼10 nM, but does not suppress the activity of 76 other protein kinases or seven lipid kinases, including Class 1 PI3Ks (phosphoinositide 3-kinases) at 1000-fold higher concentrations. Ku-0063794 is cell permeant, suppresses activation and hydrophobic motif phosphorylation of Akt, S6K and SGK, but not RSK (ribosomal S6 kinase), an AGC kinase not regulated by mTOR. Ku-0063794 also inhibited phosphorylation of the T-loop Thr308 residue of Akt phosphorylated by PDK1 (3-phosphoinositide-dependent protein kinase-1). We interpret this as implying phosphorylation of Ser473 promotes phosphorylation of Thr308 and/or induces a conformational change that protects Thr308 from dephosphorylation. In contrast, Ku-0063794 does not affect Thr308 phosphorylation in fibroblasts lacking essential mTORC2 subunits, suggesting that signalling processes have adapted to enable Thr308 phosphorylation to occur in the absence of Ser473 phosphorylation. We found that Ku-0063794 induced a much greater dephosphorylation of the mTORC1 substrate 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) than rapamycin, even in mTORC2-deficient cells, suggesting a form of mTOR distinct from mTORC1, or mTORC2 phosphorylates 4E-BP1. Ku-0063794 also suppressed cell growth and induced a G1-cell-cycle arrest. Our results indicate that Ku-0063794 will be useful in delineating the physiological roles of mTOR and may have utility in treatment of cancers in which this pathway is inappropriately activated